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ABSTRACT: To identify new potential therapeutic targets for neurodegenerative diseases, we initiated activity-based protein 
profiling studies with withanolide A (WitA), a known neuritogenic constituent of Withania somnifera root with unknown mechanism 
of action. Molecular probes were designed and synthesized, and led to the discovery of the glucocorticoid receptor (GR) as potential 
target. Molecular modeling calculations using the VirtualToxLab predicted a weak binding affinity of WitA for GR. Neurite outgrowth 
experiments in human neuroblastoma SH-SY5Y cells further supported a glucocorticoid-dependent mechanism, finding that WitA 
was able to reverse the outgrowth inhibition mediated by dexamethasone (Dex). However, further GR binding and transactivation 
assays found no direct interference of WitA. Further molecular modeling analysis suggested that WitA, although forming several 
contacts with residues in the GR binding pocket, is lacking key stabilizing interactions as observed for Dex. Taken together, the data 
suggest that WitA-dependent induction of neurite outgrowth is not through a direct effect on GR, but might be mediated through a 
closely related pathway. Further experiments should evaluate a possible role of GR modulators and/or related signaling pathways 
such as ERK, Akt, NF-κΒ, TRα, or Hsp90 as potential targets in the WitA-mediated neuromodulatory effects.
1. Introduction 
There has been a worldwide escalation over the past 
century in the prevalence of neurodegenerative diseases, such 
as Alzheimer’s, Parkinson’s and Huntington’s disease.1-4 
However, there are still no cures for these disorders and current 
treatment options are only palliative. So far, drug discovery 
efforts have focused on small molecules that mimic 
neurotrophic properties of established polypeptidal 
therapeutics, as they possess inherently better pharmacological 
properties, mainly the ability to cross the blood-brain barrier.1,5-
10 More specifically, natural products or fragments thereof have 
become of special interest.11-18 Thus, we became interested in 
withanolide A (WitA, 1, Figure 1), one of the most bioactive 
constituents in Withania somnifera, also known as 
Ashwagandha root, Indian ginseng or winter cherry.19-22 This 
ayurvedic herb has been used for centuries to treat a variety of 
ailments from arthritis, anxiety, insomnia, tuberculosis, asthma, 
to fibromyalgia, among others.21,23,24 Even today, it is sold at 
yogi or organic shops in the form of herbal supplements or in 
teas as anti-inflammatory treatment, for cognition improvement 
and anti-aging effects, increase in sexual desire and fertility, 
among others.21,25,26 A major steroidal component of this root, 
WitA, was isolated in 1971 from the roots of Withania 
somnifera (L.) DUNAL.19 This compound is one of the 900 
naturally occurring withanolides, a family of C28 steroids 
characterized by an ergostane skeleton and common 
functionalization at C1, C22 and C26.27,28 Approximately 550 
of these withanolides are considered “classic” or “unmodified”, 
with a four-ringed steroidal core (ABCD) and an appended δ-
lactone ring (E). They are known for their antitumor, anti-
inflammatory, neuroprotective, immunomodulatory and insect 
anti-feedent activities, due to well-documented 
antiproliferative, neurite-outgrowth, and cholinesterase 
inhibitory activities.23,25,27,29-33 In particular, WitA possesses 
strong neuropharmacological properties, promoting neurite 
outgrowth, reversing neuritic atrophy and aiding in synapse 
reconstruction.26,34,35 Furthermore, WitA has been suggested to 
modulate several targets involved in Alzheimer’s disease such 
as downregulation of BACE1, upregulation of ADAM10 in 
primary rat cortical neurons, and the activity of several 
secretases.36 Some of us completed a synthesis of WitA and 
performed synthetic studies to access derivatives, which were 
then evaluated for their neurite outgrowth potential.37,38 
However, our interest in this natural product extended to a 
desire to understand its underlying mechanism of action and 
elucidate further biological targets for broader applications, 
which we hoped to achieve through target identification of this 
natural product via affinity-based protein profiling (ABPP).39-42 
 
 
Figure 1. Structures of withanolide A (WitA, 1), 






2. Results and discussion 
2.1. Design of withanolide A molecular probes 
WitA exhibits putative electrophilic moieties such as an 
epoxide and two Michael acceptor systems which could 
mediate target binding via covalent addition to corresponding 
nucleophilic amino acid residues in protein active sites. 
Therefore, the WitA core scaffold was functionalized with an 
alkyne handle at different positions and these probes were 
applied in gel-based and gel-free ABPP.39-42 In this procedure, 
either SH-SY5Y human neuroblastoma or A549 human lung 
carcinoma cells were incubated for 1 to 20 hours with the probes 
at concentrations of 1–100 µM to enable labeling. The 
proteomes were then harvested and were bioorthogonally 
ligated to either a rhodamine- or biotin azide reporter tag 
through a Cu(I)-catalyzed [3+2] cycloaddition, or click 
chemistry, for visualization on fluorescent SDS-gels or mass-
spectrometry (MS) based target identification, respectively.43-45  
For a successful target profiling, the investigated 
compound needs to have a balanced reactivity and be 
modifiable with a sterically inert alkyne, distal from its reacting 
center.41 The wide-ranging biological activities of the 
withanolides have been strongly linked to covalent 
modification and thorough analysis of structure-activity 
relationship (SAR) data revealed that the 2-ene-1-one of the A-
ring was essential for activity.27 Due to several possible 
conjugate acceptors existing in the molecule and for 
completeness sake, both A- and E-ring probes were targeted. 
Our prior SAR investigations of WitA revealed that neurite 
outgrowth activity could be retained with simple C1-oximes, 
making these favorable targets for the A-ring probe synthesis.38 
These synthetic studies also revealed A-ring modification to be 
fairly facile, but functionalizing the C1 position was rather 
challenging. The δ-lactone was also found to be particularly 
stable, rendering its functionalization difficult. Ideally, the R 
group of the C1 oxime would be designed to lack bulk, 
otherwise risk disrupting possible binding interactions with the 
target(s) in the assay. In addition, the oxygenation pattern in the 
B ring could not be removed or modified to prevent important 
contacts in the binding pockets of the target(s) from being lost. 
The synthesis of inert probes was targeted as well for 
elucidation of potential off-target effects, by removing the 
conjugate acceptor ability of the molecule. 
 




2.2 Synthesis of withanolide A molecular probes 
For these synthetic studies, fresh WitA was isolated from 
powdered Ashwagandha root (0.038% yield, w/w) according to 
our previously published procedure.37,38 In the synthesis of the 
A-ring probes, the unsaturated C1 propargyl oxime 4 was 
prepared in a two-step procedure with initial formation of the 
N-H oxime and then alkylation with propargyl bromide 
(Scheme 1). Direct formation of probe 4 was not possible, 
complimentary to what was observed in previous synthetic 
studies.38 The corresponding saturated probe 5 was synthesized 
directly through propargyl oxime formation in a 75% yield, 
following a quantitative hydrogenation of WitA (1). The C3 
probes were accessed through a Wharton transposition of WitA 
(1) and oxidation to form C3 enone 10.38 The unsaturated C3 
propargyl oxime probe 6 could then be prepared directly in one 
step in a 74% yield. A mixture of oxime isomers was observed 
in this reaction after several hours, but the E-isomer could be 
exclusively obtained when the reaction time was extended (ca. 
3 days). Similarly, saturated probe 7 was accessed in 
quantitative yield, following hydrogenation. We obtained a 3:2 
ratio of separable Z:E oxime isomers. X-ray crystallography of 
the (Z)-7 isomer confirmed the configuration assignment for 
each compound.46 Only the Z-isomer of 7 was used in the target 
profiling and biological studies. 
The E-ring probes were isolated from the same reaction in 
an attempt to alkylate the C20 tertiary alcohol under phase-
transfer conditions. Propargyl ester 8 was formed during ring 





was created through further elimination of the C5 hydroxyl 
group. The structure of ester 8 was confirmed by X-ray 
crystallography.46 
2.3 Affinity-based protein profiling tests 
The six molecular probes were then screened in the ABPP 
assay. Analytical runs were performed at 1, 20 and 100 µM 
probe concentrations applied to SH-SY5Y and A549 cells. 
Analysis by SDS-PAGE and fluorescence scanning revealed 
the most intense reactivity profile for probe 9 (Figure 2).47Also 
showing specific labeling, but to a lesser degree, were probes 8, 
and the C1- and C3-propargyl oximes 4 and then 6. As proof of 
concept, the ‘inert’ saturated probes 5 and 7 did not show any 
specific labeling in these assays, serving as a support for the 
pharmacological hypothesis for the mode of action of WitA. 
These results nicely correlate with the expected chemical 
reactivity of each probe, as the unsaturated oxime of probe 4 is 
not only less electrophilic than the corresponding enones of 
probes 8 and 9, but possible steric congestion within the binding 
pocket of the targets with the propargylic oxime group at the 
C1-position could very well explain the less specific labeling 
observed for probe 4 over probes 8 and 9. 
Figure 2. Representative SDS-PAGE showing analytical 
labeling of cytosol fraction of SH-SY5Y cells incubated with 
all six WitA probes (at a 1, 10 or 100 µM concentration) for 6 
hours in PBS at 0.1% DMSO. Fluorescent marker (FM) lane 
designates protein size in kDa. No bands were found for the 
membrane fractions (data not shown) 
    
Table 1. Targets in Common from Activity-Based Profiling with WitA Probes 4, 8, and 9.  




1 sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
ATP2A2 8, 9 
2 voltage-dependent anion-selective 
channel protein 2 
VDAC2 8, 9 
3 reticulon-4 RTN4 4, 8, 9 
4 cytochrome b5 type B CYB5B 4, 8, 9 
5 cytoskeleton-associated protein 4 CKAP4 4, 8, 9 
6 microsomal glutathione S-transferase 3 MGST3 4, 8, 9  
7 minor histocompatibility antigen H13 HM13 4, 8 





9 glutathione S-transferase omega-1 GSTO1 8, 9 
10 mitochondrial carrier homolog 2 MTCH2 8, 9 
11 glucocorticoid receptor NR3C1 4, 
8, 9 





13 voltage-dependent anion-selective channel protein
3 
VDAC3 8, 9 
14 prostaglandin E synthase 2 PTGES
2 
4, 8 
15 histidine-tRNA ligase, cytoplasmic HARS 4, 8 
Figure 3. SILAC data volcano plots of WitA probes 8 (A), 9 (B) and 4 (C): fold-change, enrichment extent normalized to the DMSO 
control (log2 enrichment) versus statistical significance (–log10 p-value); p-value from ANOVA statistical model; top hits designated 






In order to elucidate the identity of all targets, quantitative, 
gel-free ABPP was performed via stable isotope labeling of 
amino acids in cell culture (SILAC) with the top three probes 
exhibiting the most pronounced labeling effect from the 
analytical experiments.48 A549 cells were cultivated in media 
containing either heavy or light isotope labeled amino acids. 
These cells were then treated with the probes 4, 8 or 9 at 10 µM 
concentration (or DMSO control). The cells were then lysed, 
pooled with the control, clicked to a biotin-azide linker49 and 
enriched using avidin beads. The enriched proteins were 
digested using trypsin. The resulting solution was analyzed by 
high-resolution liquid chromatography tandem MS (LC-
MS/MS). Log2(isotopic ratios) values of zero indicate no 
enrichment as compared to the DMSO control, and ratios 
greater than 1-fold with a p-value of <0.05 were regarded as 
significant hits. These top hits with our three active probes are 
depicted in the upper right hand area of the corresponding 
volcano plots (A-C, Figure 3).50 In addition, the hits shared in 
common between the three probes were identified and ranked 
according to enrichment and p-value to give the 15 hits listed in 
Table 1 (Figure 3).51 
 
Figure 4. Predicted GR binding affinities [–log(Kcalc)] of 
compounds of interest calculated using VirtualToxLab. 
While several of these hits might be of interest in 
understanding neurological pathways, we were particularly 
interested in the glucocorticoid receptor (GR, systematic name: 
NR3C1). The GR is a 78.7 kDa protein that belongs to the 
family of nuclear receptors and regulates genes for 
development, metabolism and immune response, through either 
transactivation or transrepression mechanisms.52-54 Molecules 
that modulate this target, i.e. glucocorticoids, are mediators of 
stress response. A 2014 report by Terada and co-workers found 
that an antagonist of GR, such as  mifepristone (RU486, Mife, 
3, Figure 1), can induce neurite outgrowth by phosphorylation 
of Akt (protein kinase B, PKB) and extracellular regulated 
kinase 1/2 (ERK1/2), which are involved downstream in nerve 
growth factor (NGF)-induced neurite outgrowth.55 At the same 
time, GR agonists like dexamethasone (Dex, 2, Figure 1) impair 
neurite outgrowth through interference of 
activation/phosphorylation of these same targets. In addition, 
treatment with Mife reversed the inhibitory activity of Dex on 
neurite outgrowth via the same NGF-induced Akt and ERK1/2 
phosphorylation pathways. Mife has been previously 
demonstrated to reverse effects of glucocorticoid (GC) 
treatment and restore neurogenesis in cells,56-58 and has become 
associated with neuroprotection,59-62 implying that this is a 
glucocorticoid-dependent process.63 It is also known that GCs 
exacerbate clinical symptoms and neurodegenerative processes 
(in vivo and in vitro),64 and that GR-mediated transrepression 
has been linked to prevent neurodegeneration in Huntington’s 
disease.65 Therefore, the present study investigated whether the 
WitA-dependent effect on neurite outgrowth might be mediated 
by GR. 
2.4 Computational approaches 
We initiated our investigation of a potential binding of WitA to 
GR with the computational modeling program VirtualToxLab,65 
an in silico anti-target screening tool.66-67,68 This technology is 
based on an automated, flexible docking calculation combined 
with multi-dimensional quantitative structure–activity 
relationship (QSAR) protocol that simulates and quantifies the 
binding of small molecules towards a series of currently 16 
proteins, known or suspected to trigger adverse effects: 10 
nuclear receptors (androgen receptor, estrogen receptor α , 
estrogen receptor β , GR, liver X receptor, mineralocorticoid 
receptor, peroxisome proliferator-activated receptor γ, 
progesterone receptor, thyroid receptor α , thyroid receptor β ), 
four members of the cytochrome P450 enzyme family 
(CYP1A2, CYP2C9, CYP2D6, CYP3A4), a cytosolic 
transcription factor (aryl hydrocarbon receptor) and a potassium 
ion channel (hERG). While binding modes and affinities were 
predicted towards all 16 target proteins comprising the 
VirtualToxLab, the interest was mainly focused on GR.69 GR 
agonist Dex was predicted to bind with 1.7 nM affinity to GR 
(exp. = 2.0 nM), while the predicted affinity of the known GR 
antagonist Mife was 2.6 nM (exp. = 15 nM) (Figure 4). For 
WitA, a weaker affinity of 5.7 µM for GR was predicted, and 
the ABPP-active WitA probes were predicted to bind with 
similar or lower affinity than WitA. Affinities computed with 
the VirtualToxLab represent a “thermodynamic” estimate only 
and do not account for the kinetic stability of the ligand–protein 
complex. To address this issue, WitA was probed further 
through iterative inspection in real-time 3D by molecular 
dynamics (MD) simulations, which could require correcting the 
“thermodynamic affinity” in either direction. Both Dex and 
WitA demonstrated stable ligand–protein interactions 
throughout the entire 100 ns MD simulation.70 Each complex 
was further stabilized by the dynamic relaxation of the 
technique, indicating that the “thermodynamic” binding 
affinities might be slightly higher than those predicted by the 
VirtualToxLab. 
2.5 Neurite outgrowth GR competition assays 
We then wanted to clarify if WitA’s neurite outgrowth activity 
was linked to its ability to modulate GR. Therefore, we 
performed in vitro neurite outgrowth experiments with Dex, 
Mife, and WitA. Human neuroblastoma SH-SY5Y cells were 
cultured in DMEM/F-12 media supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin at 37°C in a 
humidified atmosphere (5% CO2 content). For neurite 
outgrowth experiments the cells were seeded on collagen-
coated 24-well plates and treated with 1 µM of the 





all-trans retinoic acid (ATRA, RA) as a positive control. After 
a 6-day incubation, the media was removed and cells were fixed 
with a 4% buffered formaldehyde solution and stained with 
modified Giemsa stain to visualize the cell bodies for 
subsequent imaging under a phase-contrast microscope. All 
assays were performed in triplicate, with 6−11 images randomly 
taken between biological replicates, and at least 350 cells 
counted per treatment per plate (three wells/plate per treatment). 
Cells having at least one neurite with a length of more than 50 
µm were counted as differentiated (positive). The ratio of 
neurite positive cells to total cells was calculated and error is 
represented by the standard error of the mean (SEM).  
  
  
Figure 6. Neurite outgrowth of human SH-SY5Y cells treated 
with WitA (1), Dex (2), Mife (3), and WitA probes (4−9). 0.1% 
DMSO and RA are vehicle and positive controls. Data 
represents mean ± SEM from three independent experiments in 
triplicates For statistical analysis, ANOVA and post hoc tests 
(Dunnett’s Method and Tukey Kramer Method) were used.77 
From these experiments, we observed that all six 
withanolide probes induced neurite outgrowth of SHSY5Y cells 
(Figure 6). All four oxime probes (4−7) induced outgrowth to a 
similar extent as WitA and Mife and showed significantly 
higher activity than propargyl ester probes 8 and 9.72 
Nevertheless, the propargyl esters still showed outgrowth 
activity comparable to the RA positive control. Moreover, WitA 
was also able to counteract the neurite outgrowth inhibition of 
Dex, suggesting that WitA is potentially acting as a GR 
antagonist, similar to Mife (Figure 7). The same effect was 
observed for both propargyl ester probes 8 and 9. Interestingly, 
impaired neurite outgrowth was observed in the simultaneous 
treatments of both Dex and Mife with unsaturated C1 propargyl 
oxime 4, within the statistical significance of the vehicle DMSO 
control (indicating no outgrowth). 
 
Figure 7. Neurite outgrowth in GR competition experiment of 
WitA (1), probes (4, 8, 9) with Dex (2) and Mife (3) in human 
SH-SY5Y cells. 0.1% DMSO and RA are vehicle and positive 
controls. Data represents mean ± SEM from three independent 
experiments in triplicates For statistical analysis, ANOVA and 
post hoc tests (Dunnett’s Method and Tukey Kramer Method) 
were used.79 
2.6 GR and MR transactivation bioassays 
We then performed in vitro assays to investigate whether WitA 
might act as an antagonist of GR activity. HEK-293 cells were 
transiently transfected with human GR under the control of a 
GR sensitive luciferase promoter (Figure 8A). Additionally, the 
closely related mineralocorticoid receptor (MR) was tested for 
modulation by WitA (Figure 8B). 10 µM WitA was not able to 
stimulate GR-mediated activation of the luciferase reporter 
gene, whereas the MR was weakly activated. However, and 
more importantly regarding GR-dependent neuronal outgrowth, 
no antagonistic effect on the cortisol-dependent GR activation 
could be observed with 1 µM WitA. In addition, neither an 
agonistic nor an antagonistic activity of WitA on MR function 
could be observed. Thus, a direct interference of WitA with the 
GR and the MR could not be demonstrated within this cell-
based assays.  
To exclude the possibility that either WitA is under the 
control of efflux transport or that it was unable to cross the cell 
membrane, a GR binding assay was performed under cell-free 
conditions. Lysates of SF9 cells expressing recombinant human 
GR were incubated in the presence of 10 nM 3H-dexamethasone 
as a tracer and the unlabeled competitor (either 10 µM Dex or 
1 or 10 µM WitA) until the binding equilibrium was reached. 
The GR bound fraction of 3H-dexamethasone is displayed in 
Fig. 9. Unlike with unlabeled Dex, WitA could not displace 3H-
Dex from the GR binding site at concentrations up to 10 µM 
(Figure 9). This indicates that WitA is not a ligand for GR, as 
could be predicted by the calculated binding affinities of WitA, 
discussed above. These results are also in line with those from 
the transactivation assays, indicating that WitA does not induce 































































Figure 8. Effect of WitA on the modulation of GR and MR. 
Impact of WitA on GR (A) and MR (B) transactivation in HEK-
293 cells transfected with a corticosteroid receptor sensitive 
luciferase reporter gene and human GR or human MR. Cells 
were incubated for 24 h in the presence or absence of 100 nM 
cortisol (F) or 1 µM Mife for GR, and 10 nM aldosterone (Aldo) 
or 1 µM spironolactone (Spiro) for MR. WitA was added at 1 
or 10 µM. Data were normalized to vehicle control (0.05% 
DMSO) and represent mean ± SD from a representative 
experiment performed in triplicates. 
 
Figure 9. Displacement of radiolabeled Dex from GR with 
unlabeled competitor (WitA or Dex). Values were normalized 
to the maximal binding activity of 10 nM 3H-Dex. 
2.7 GR docking study 
To computationally rationalize the results obtained from 
the transactivation and binding assays, docking studies 
comparing WitA and Dex for important binding interactions in 
the GR binding pocket were conducted using the same crystal 
structure as in the VirtualToxLab screening (PDB code 1M2Z. 
Figure 10A illustrates docked Dex (grey) and WitA (purple) in 
the GR binding site. The automatically generated 
pharmacophore interaction pattern revealed different residues 
forming hydrophobic and hydrogen bond (H-bond) interactions 
for Dex (Figure 10B) and WitA (Figure 10C). Generally, the 
docking calculations displayed different conformations for 
WitA, whereas Dex was found to fit in one major pose. Dex is 
stabilized by H-bond interactions in the GR binding pocket, 
exerted by oxygen and nitrogen atoms of the following residues: 
Asn564, Gln570, Arg611, Gln642 and Thr739. These 
interactions are known to be important for GR activation.80 
However, the H-bond interactions of Wit A with the GR adopt 
clearly greater distances and two of five hydrogen bonds 
involve a sulfur center (Met601 and Cys736). These 
interactions are generally regarded as weak H-bonds compared 
to interactions including oxygen or nitrogen groups. 
Furthermore, WitA has less hydrophobic interaction partners 
than Dex. Although we were able to dock WitA into the binding 
pocket of GR and therefore confirmed the VirtualToxLab 
screening results, the interaction pattern shows distinctively less 
favorable interactions compared to Dex. This may explain the 
inability of WitA to displace Dex from GR in the lysate binding 
assay. A weak but covalent binding of WitA to GR might be 
missed by the docking calculations; however, in vitro 
verification assessments excluded this possibility. 
Nevertheless, regarding its effect on neurite outgrowth, one 
would expect an antagonistic action of WitA on GR function. 
In contrast to the agonist bound position, active antagonist 
conformations can displace the helix 12 and thereby trigger a 
molecular shift to alter the coactivator site into the corepressor 
site.81 Docking of WitA into a GR X-ray structure with Mife as 
co-crystallized ligand (PDB code 1NHZ) showed no 
interference of WitA with the helix 12 (data not shown). Thus, 
the molecular modeling does not support a direct antagonistic 
activity of WitA on GR, in line with the lack of antagonistic 
activity of WitA in the transactivation assay. 
 
Figure 10. Docking of Dex and WitA into the binding pocket 
of GR. (A) Dex (grey) and WitA (purple) docked into the GR 
binding site. Amino acid residues important for binding are 
depicted as sticks. Yellow spheres display H-bond features 
important for binding. Arrows indicate H-bonds with the 
corresponding distance between the ligand and the residue of 
the binding pocket (grey numbering belong to Dex and purple 





interactions of part B and C. (B) Two-dimensional 
representation of the binding interactions of Dex with GR. (C) 
Binding interactions of WitA and GR are shown. Hydrophobic 
interactions are depicted in yellow, hydrogen bond acceptors in 
red and hydrogen bond donors in green. 
3. Conclusion 
In this study, we investigated the GR as a target for WitA–
dependent neurite outgrowth activity. While results from target 
profiling, VirtualToxLab screening and in vitro GR competition 
neurite outgrowth assays supported this GR hypothesis, 
additional GR transactivation and binding assays and further 
docking studies did not support a direct interaction of WitA as 
GR antagonist causing the neurite outgrowth effect. However, 
we did confirm that WitA is able to reverse the neurite 
outgrowth inhibitory activity of Dex, similar to GR antagonist 
Mife. Nevertheless, a GR indirect effect of WitA by interfering 
with GR-related targets such as ERK, Akt, NF-κΒ, TRα, or 
Hsp90 might be possible. It is possible that WitA affects 
additional targets via a reversible binding mode, which we 
could not detect with the current ABPP design and would 
require the incorporation of photoreactive groups. Interactions 
have been already established between these targets and Mife, 
withanolide extract or withaferin A, and it is possible that we 
identified GR as a positive hit for WitA in our pulldown assay 
when WitA was actually modulating one of these targets instead 
of GR directly. 24, 54, 58, 60, 76-86 Ongoing efforts are being made to 
assess a potential connection through these targets. In addition, 
we are pursuing additional studies to follow-up on the other 14 
proteins-of-interest, identified in our ABPP profiling study. 
4. Experimental 
4.1. General 
Commercial reagents and solvents were purchased from 
Sigma-Aldrich, Alfa Aesar, Fisher Scientific, Acros Organics, 
or Fluorochem and used as received, unless otherwise noted. 
Deuterated solvents were purchased from Cambridge Isotope 
Laboratories, Inc. (Andover, MA, USA). Flash chromatography 
was carried out on Silicycle 60 Å silica gel (40−63 µm, 
230−400 mesh. Eluents and Rf’s are indicated. Analytical thin 
layer chromatography was performed using Merck silica gel 60 
F254 plates (0.25mm thickness) and was visualized by UV light 
and fluorescent indicator, with or without heating (potassium 
permanganate, p-anisaldehyde or aqueous ceric ammonium 
molybdate stain). 
All 1H spectra were recorded on a Bruker Avance III 
400MHz (400 MHz for 1H and 101 MHz for 13C) or Bruker 
Avance III 500MHz spectrometer (500 MHz for 1H and 126 
MHz for 13C). Chemical shifts (δ-values) are reported in parts 
per million (ppm) relative to CDCl3 (7.26 ppm for 1H NMR and 
77.0 ppm for 13C NMR). 1H NMR spectra are tabulated in the 
order: chemical shift, multiplicity, coupling constant (J in Hz), 
number of protons. Multiplicity is reported as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet or 
unresolved; ap = apparent, br = broad. 
Infrared spectra were recorded on a Varian 800 FT-IR ATR 
spectrophotometer and values are reported as frequency of 
absorptions in cm-1. All HRMS-ESI spectra were recorded by 
the mass spectrometry service of the chemistry department at 
the University of Basel on a QTOF-ESI spectrophotometer 
(bruker MaXis 4G). Fragment ions are given in m/z with 
relative intensities (%) in parentheses. Melting points (m. p.) 
were collected on a Büchi B-545 apparatus in open capillaries. 
Optical rotations were measured on a Jasco P-2000 digital 
polarimeter with a sodium lamp (D-589 nm) in a 1 dm 
cylindrical cell (1 mL cell volume) and are reported as follows: 
[𝛼𝛼]𝝀𝝀𝑇𝑇°𝐶𝐶 (c = g/100 mL, solvent). 
4.2. Isolation of withanolide A 
Powdered Ashwagandha root93 (5 × 100 g + 10 × 250 g, 
purchased from Yoga Vidya, Horn-Bad Meinberg, Germany) 
was stirred in 500 g batches in a covered 2 L Erlenmeyer flask 
with 1.25 L of methanol overnight. The brown slurry was then 
transferred to a 10 cm diameter column with an additional 100 
mL of methanol to rinse. The MeOH extract was allowed to 
percolate out (drip out by gravity) and was collected (~2 h). An 
additional 650 mL of methanol was added to the column, and 
allowed to percolate further (~3 h). The methanol remaining in 
the wet root powder was flushed out using nitrogen flow. The 
extract was carefully concentrated in vacuo. This procedure was 
repeated five times, until extract was obtained for all 3 kg of the 
Ashwangandha root. 
The combined methanol extract (combined volume of ~1.5 
L) was washed with pentane (3 × 500 mL) to remove grease and 
other apolar compounds, and was then carefully concentrated in 
vacuo to afford a thick, brown oil. To remove the more polar 
substances, this oil was taken up in EtOAc (500 mL), the 
organic layer was separated and the aqueous layer was washed 
2 more times with EtOAc (200 mL). The combined EtOAc 
extracts were then washed with H2O (3 × 500 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to afford 17.4 g of a 
brown oil. All aqueous extracts were checked for withanolide 
A by TLC to make sure none was still present before disposal. 
The crude oil was purified by flash column 
chromatography (FCC, wet load) with 70% to 100% 
EtOAc/pentanes, and then 5% and 20% MeOH/EtOAc, to 
afford 5.68 g of a yellow solid (collected during 80-100% 
EtOAc/pentane and 5% MeOH/EtOAc eluents). This solid was 
purified again by FCC with 40:1 DCM:MeOH to afford 2.1g of 
a yellow/white solid, which was then triturated with cold ether 
to afford 1.6 g of a white solid. A series of additional columns 
with 100X-250X silica gel, with either 8:1:1 
EtOAc:CHCl3:Hexane (dry load), or 40:1 DCM:MeOH (dry 
load), or 80% EtOAc/Hex (wet load with CHCl3) as eluents. A 
total of 1.03 g of pure Withanolide A was obtained as white 
solid, as shown in Figure S1 in 0.038% yield (see supporting 
information). Also noteworthy, approximately 200 mg of 
Withanolide B (S1), or C20-dehydroxywithanolide A, was 
obtained as a white solid; WitB Rf = 0.65 (8:1:1 
EtOAc/hexane/CHCl3).94 Analytical data of Withanolide A (1): 
[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 = +87.9° (c = 0.21, CHCl3) [Lit: +86.8 when c = 1.15, 
CHCl3]. IR (film) 𝜈𝜈�  = 3437, 2984, 2937, 1703, 1679, 1446, 
1374, 1295, 1220, 1188, 1137, 1099, 1073, 1028, 955, 909, 883, 
815, 800, 727, 648, 612 cm-1. 1H NMR (400 MHz, CDCl3) δ 





1.0 Hz, 1H), 4.21 (dd, J = 13.4, 3.5 Hz, 1H), 3.32 (dd, J = 4.0, 
2.1 Hz, 1H), 3.12 (d, J = 1.5 Hz, 1H), 3.04 (d, J = 3.9 Hz, 1H), 
2.79 – 2.65 (m, 2H), 2.52 (ddd, J = 18.8, 5.2, 1.0 Hz, 1H), 2.43 
– 2.35 (m, 1H), 2.37 (d, J = 1.3 Hz, 1H), 2.14 – 1.98 (m, 3H), 
1.96 (s, 3H), 1.89 (s, 3H), 1.86 – 1.80 (m, 1H), 1.78 (ddd, J = 
10.6, 10.6, 2.2 Hz, 1H), 1.61 – 1.34 (m, 7H), 1.32 (s, 3H), 1.18 
(s, 3H), 0.96 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 203.3, 
166.2, 149.0, 139.8, 129.1, 122.2, 81.1, 75.2, 73.4, 57.5, 56.5, 
54.6, 52.1, 51.1, 44.0, 40.5, 36.9, 35.7, 35.2, 31.8, 23.3, 21.9, 
21.9, 21.2, 20.7, 14.9, 13.9, 12.6. HRMS (ESI): Exact mass 
cald for C28H39O6 [M+H]+, 471.3. Found 471.3. 95 





withanolide A hydroxylamine S2 was prepared according to a 
modified procedure (see supporting information for details).96 
Withanolide A hydroxylamine S2 (10 mg, 0.021 mmol) was 
taken up in DMSO (100 µL, 0.2 M) in a round bottom flask with 
magnetic stir bar under argon. KOH pellets (4 mg, 0.062 mmol, 
3 equiv.) were added and dissolved to give a milky yellow 
solution. Then, added propargyl bromide (10 µL, 0.062 mmol, 
80% by weight in toluene, 3 equiv.) and the solution turned 
brown. The reaction stirred for 3 hours and then added 1M HCl 
solution. The reaction mixture was extracted with DCM (3×), 
and then dried the combined organic layers over Na2SO4, 
filtered and concentrated in vacuo to afford a yellow oil. The 
crude product was purified by flash column chromatography 
with silica gel (×200 by weight) and with 80:1 DCM:MeOH as 
the eluent to afford the C1 propargyl oxime as a clear oil (6.3 
mg, 58% yield). Analytical data for 4: TLC Rf = 0.67 (8:1:1 
EtOAc/hexane/CHCl3, CAM stain). [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪  = +171.5° (c = 
0.275, CHCl3) IR (film) 𝜈𝜈�  = 3526, 3279, 2941, 2919, 2359, 
2325, 2212, 2050, 1985, 1705, 1446, 1381, 1317, 1290, 1130, 
1095, 1039, 1003, 906, 876, 825, 788, 651, 620 cm-1. 1H NMR 
(400 MHz, CDCl3) δ 6.67 (ddd, J = 10.3, 2.7, 1.1 Hz, 1H), 6.01 
(ddd, J = 10.3, 4.7, 2.5 Hz, 1H), 4.64 (dd, J = 2.4, 1.1 Hz, 2H), 
4.21 (dd, J = 13.3, 3.5, 1H), 3.31 (dd, J = 3.7, 2.0 Hz, 1H), 3.01 
(d, J = 3.9 Hz, 1H), 2.96 (d, J = 2.6 Hz, 1H), 2.91 – 2.82 (m, 
1H), 2.52 – 2.32 (m, 5H), 2.16 – 1.98 (m, 3H), 1.95 (s, 3H), 1.89 
(s, 3H), 1.87 – 1.77 (m, 2H), 1.63 – 1.34 (m, 7H), 1.33 (s, 3H), 
1.09 (s, 3H), 0.98 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.2, 
159.2, 148.9, 131.4, 122.2, 118.3 81.2, 80.3, 75.3, 74.0, 71.4, 
61.4, 57.5, 56.8, 54.6, 52.4, 45.5, 44.1, 40.6, 37.4 36.7, 35.4, 
31.9, 23.4, 22.7, 22.0, 21.3, 20.7, 16.1, 14.0, 12.6. HRMS 
(ESI): Exact mass cald for C31H41NO6 [M+H]+, 524.3. Found 
524.3. 
General procedure A for oxime ethers 5–7 
To a solution of ketone (1.0 equiv.) in pyridine (freshly 
distilled over KOH pellets, 1.0 equiv.) was added the O-
propargylhydroxylamine hydrochloride (S4, 3.0 equiv, see 
supporting information for synthetic details of S4) in an oven-
dried round-bottom flask with stir bar (equipped with oven-
dried reflux condenser), and the mixture was heated at 70 °C for 
the indicated time. The solvent was then removed under high 
vacuum, and the resulting residue was dissolved in CH2Cl2. 
Saturated NH4Cl (aqueous) solution was added and the aqueous 
phase was extracted with CH2Cl2 (3×). The combined organic 
phases were dried over Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column 
chromatography under the indicated conditions to yield the 





dimethyl-5,6-dihydro-2H-pyran-2-one (5): saturated C1 
propargyl oxime 5 was made according to general procedure A. 
The reaction was performed on 21 μmol scale of saturated 
withanolide A (S3, see supporting information for synthetic 
details) for 7 hours. Purification by flash column 
chromatography was performed with silica gel (150X by 
weight) with 120:1 CH2Cl2:MeOH as the eluent, and afforded 5 
as a white solid in a 75% yield. Analytical data for 5: TLC Rf = 
0.64 (50% EtOAc/pentanes, CAM stain); [Rf (starting material 
1) = 0.49 (50% EtOAc/pentanes)]. mp = 200−202 °C. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 
= +93.4° (c = 0.14, CHCl3). IR (film) 𝜈𝜈� = 3267, 2944, 2361, 
2338, 2166, 1703, 1441, 1384, 1314, 1291, 1178, 1133, 1095, 
1041, 1002, 896, 761, 686, 631 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 4.66 – 4.57 (m, 2H), 4.21 (dd, J = 13.4, 3.6 Hz, 1H), 
3.30 – 3.22 (m, 2H), 2.99 (d, J = 4.0 Hz, 1H), 2.92 (s, 1H), 2.61 
(dddd, J = 9.2, 2.9, 2.9, 2.9 Hz, 1H), 2.40 (dd, J = 2.4, 2.4 Hz, 
1H), 2.39 – 2.32 (m, 2H), 2.11 (dd, J = 17.4, 2.9 Hz, 1H), 2.08 
– 1.96 (m, 3H), 1.95 (s, 3H), 1.95 – 1.90 (m, 1H), 1.89 (s, 3H), 
1.87 – 1.82 (m, 1H), 1.79 (ddd, J = 10.5, 10.5, 2.3 Hz, 1H), 1.75 
– 1.33 (m, 8H), 1.32 (s, 3H), 1.21 – 1.13 (m, 1H), 1.11 (s, 3H), 
0.96 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.3, 162.4, 
149.0, 122.2, 81.2, 80.7, 75.3, 73.8, 72.5, 61.0, 57.6, 57.3, 54.5, 
52.3, 47.3, 44.4, 40.6, 36.9, 35.3, 32.6, 31.9, 23.2, 22.1, 22.1, 
21.3, 20.7, 20.4, 20.2, 16.2, 14.1, 12.6. HRMS (ESI): Exact 





cyclopenta[1,2]phenanthro[9,10-b]oxiren-2-one (10): C3 enone 
(10) was accessed through our previously published 
procedure95b from withanolide A (1) on a 0.21 mmol scale: 
through the epoxy ketone (S5, 88% yield) intermediate, and a 
Wharton transposition to allylic alcohol (S6, 65% yield). Then, 
powdered 4Å molecular sieves (200 mg, 40X by weight) were 
added to the solution of allylic alcohol S6 (25 mg, 52.7 μmol) 
in CH2Cl2 (4 mL, 0.013 M) in an oven dried round bottom flask 
with magnetic stir bar. This mixture stirred for 5 minutes at 
room temperature under argon, when pyridinium dichromate 
(36 mg, 94.1 μmol, 1.8 equiv.) was added and the mixture 
stirred at room temperature for 2 hours and 20 minutes. The 
mixture was then filtered over a celite pad, washing with 
CH2Cl2. The combined organic layer was successively washed 
with 1 N HCl (2 × 30 mL,) and brine (60 mL), and then dried 
over Na2SO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography (eluent: 
80:1 CH2Cl2/MeOH) to obtain enone 10 (21.6 mg, 45.9 μmol, 





Analytical data for 10: TLC Rf = 0.5 (EtOAc). mp = 
252−255 °C. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 = +71.1° (c = 0.385, CHCl3). IR (film) 𝜈𝜈� 
= 3394, 2984, 2946, 1693, 1658, 1471, 1385, 1321, 1296, 1269, 
1187, 1182, 1136, 1116, 1064, 1019, 986, 916, 815, 762, 745 
cm-1. 1H NMR (500 MHz, CDCl3) δ 6.97 (d, J = 10.3 Hz, 1H), 
5.99 (dd, J = 10.2, 0.9 Hz, 1H), 4.21 (dd, J = 13.4, 3.5 Hz, 1H), 
3.36 (dd, J = 3.9, 2.5 Hz, 1H), 3.16 (d, J = 2.0 Hz, 1H), 3.09 (d, 
J = 3.8 Hz, 1H), 2.85 (dd, J = 17.0, 2.1 Hz, 1H), 2.66 (dd, J = 
17.0, 1.0 Hz, 1H), 2.45 – 2.32 (m, 2H), 2.25 – 1.97 (m, 3H), 
1.96 (s, 3H), 1.89 (s, 3H), 1.88 – 1.81 (m, 2H), 1.72 – 1.34 (m, 
8H), 1.32 (s, 3H), 1.16 (s, 3H), 0.98 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 196.8, 166.1, 153.1, 148.9, 128.1, 122.2, 81.1, 
75.2, 72.1, 57.7, 56.7, 54.4, 51.7, 46.6, 44.3, 42.8, 40.1, 35.7, 
35.3, 31.8, 23.1, 22.2, 21.3, 20.8, 20.7, 20.5, 13.9, 12.6. HRMS 







dimethyl-5,6-dihydro-2H-pyran-2-one (6): C3 propargyl oxime 
6 was made according to general procedure A. The reaction was 
performed on 12 μmol scale of enone 10, with a reaction time 
of 3 days. Purification by flash column chromatography was 
performed with silica gel (1000X by weight) with 120:1 and 
then 80:1 CH2Cl2:MeOH as the eluent, and afforded (E)-6 (4.6 
mg, 8.8 μmol, 74% yield) as a white solid. If the reaction time 
was reduced to 4 hours, then both oxime diastereomers were 
obtained (86% yield of 1:1 E:Z ratio on 10 μmol scale of enone 
10). Only the (E)-6 isomer was used in the biological studies. 
Analytical data for (E)-6: TLC Rf = 0.67 (50% EtOAc/pentanes 
or 8:1:1 EtOAc/hexane/CHCl3, CAM stain). mp = 185-187 °C 
(decomposition). [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 = +81.4° (c = 0.5, CHCl3). IR (film) 𝜈𝜈� = 3518, 3303, 2939, 2360, 1703, 1461, 1386, 1319, 1287, 
1132, 1099, 1043, 1007, 914, 731, 682, 648 cm-1. 1H NMR (400 
MHz, CDCl3) δ 6.27 (d, J = 10.2 Hz, 1H), 6.18 (d, J = 10.1 Hz, 
1H), 4.71 (d, J = 2.4 Hz, 2H), 4.20 (dd, J = 13.3, 3.4 Hz, 1H), 
3.33 (dd, J = 2.9, 2.9 Hz, 1H), 3.18 – 3.08 (m, 2H), 3.04 (s, 1H), 
2.63 (d, J = 17.7 Hz, 1H), 2.49 (dd, J = 2.4, 2.4 Hz, 1H), 2.43-
2.33 (m, 2H), 2.19 – 1.99 (m, 3H), 1.95 (s, 3H), 1.89 (s, 3H), 
1.86 – 1.78 (m, 2H), 1.68 – 1.55 (m, 3H), 1.50 – 1.37 (m, 4H), 
1.31 (s, 3H), 0.98 (s, 3H), 0.96 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 166.1, 154.4, 148.9, 140.1, 122.9, 122.2, 81.1, 77.4, 
75.2, 74.7, 69.4, 61.8, 57.7, 57.1, 54.4, 51.8, 44.3, 42.1, 40.2, 
35.9, 35.2, 33.6, 31.8, 23.1, 22.2, 21.3, 20.7, 20.7, 20.5, 13.8, 
12.6. HRMS (ESI): Exact mass cald for C31H42NO6 [M+H]+, 
524.3. Found 524.3.  
Analytical data for (Z)-6: Also isolated as a white solid. 
TLC Rf = 0.58 (50% EtOAc/pentanes or 8:1:1 
EtOAc/hexane/CHCl3, CAM stain). mp = 118-120 °C. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 
= +75.6° (c = 0.34, CHCl3). IR (film) 𝜈𝜈� = 3521, 3295, 2929, 
2362, 2340, 1704, 1461, 1427, 1383, 1319, 1288, 1133, 1099, 
1043, 1007, 972, 917, 816, 763, 731, 647 cm-1. 1H NMR (400 
MHz, CDCl3) δ 6.75 (d, J = 10.3 Hz, 1H), 6.30 (d, J = 10.4 Hz, 
1H), 4.68 (dd, J = 2.4, 1.0, 2H), 4.20 (dd, J = 13.4, 3.5 Hz, 1H), 
3.33 (dd, J = 3.1, 1H), 3.14 – 3.05 (m, 2H), 2.84 (d, J = 16.2 Hz, 
1H), 2.66 (d, J = 16.0 Hz, 1H), 2.46 (dd, J = 2.4 Hz, 1H), 2.44 
– 2.33 (m, 2H), 2.20 – 2.10 (m, 3H), 1.95 (s, 3H), 1.89 (s, 3H), 
1.87 – 1.75 (m, 2H), 1.69 – 1.55 (m, 2H), 1.52 – 1.35 (m, 6H), 
1.32 (s, 3H), 1.02 (s, 3H), 0.96 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 166.1, 151.4, 148.9, 143.0, 122.2, 115.9, 81.1, 80.1, 
75.2, 74.4, 70.1, 61.5, 57.6, 57.0, 54.4, 51.7, 44.3, 42.8, 40.1, 
36.9, 35.9, 35.3, 31.8, 29.8, 23.1, 22.2, 21.2, 20.9, 20.7, 20.7, 
13.8, 12.6. HRMS (ESI): Exact mass cald for C31H42NO6 





dimethyl-5,6-dihydro-2H-pyran-2-one (7): Saturated C3 
propargyl oxime 7 was made according to general procedure A. 
The reaction was performed on 8 μmol scale of ketone S7 (for 
details of S7, see supporting information), with a reaction time 
of 5 hours. The 3:2 ratio of Z:E isomers could be separated by 
flash column chromatography purification with silica gel 
(1000X by weight) with 120:1 and then 80:1 CH2Cl2:MeOH as 
the eluent. Saturated C3 propargyl oxime 7 (4.1 mg, 7.8 μmol, 
>99% yield) was obtained as a white solid. Only the (E)-7 
isomer was used in the biological studies. Analytical data for 
(Z)-7: TLC Rf = 0.55 (50% EtOAc/pentanes, CAM stain). mp 
= 200-204 °C (decomposition). [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪  = +65.6° (c = 0.25, 
CHCl3). IR (film) 𝜈𝜈�  = 3531, 3287, 2943, 2361, 2338, 2111, 
2051, 1985, 1705, 1462, 1425, 1335, 1319, 1287, 1181, 1133, 
1098, 1047, 1006, 896, 858, 784, 735, 631   cm-1. 1H NMR 
(400 MHz, CDCl3) δ 4.72 – 4.58 (m, 2H), 4.20 (dd, J = 13.3, 
3.5 Hz, 1H), 3.33 – 3.26 (m, 1H), 3.20 (d, J = 15.6 Hz, 1H), 
3.01 (d, J = 3.8 Hz, 1H), 2.86 (d, J = 2.1 Hz, 1H), 2.54 – 2.41 
(m, 1H), 2.45 (dd, J = 2.4, 2.4 Hz, 1H), 2.40 – 2.31 (m, 3H), 
2.28 (dd, J = 15.7, 2.1 Hz, 1H), 2.15 – 1.98 (m, 3H), 1.95 (s, 
3H), 1.89 (s, 3H), 1.86 – 1.64 (m, 3H), 1.62 – 1.53 (m, 1H), 1.48 
(dd, J = 9.8, 9.8 Hz, 1H), 1.41 – 1.32 (m, 4H), 1.30 (s, 3H), 1.28 
– 1.23 (m, 2H), 1.17 – 1.06 (m, 1H), 0.93 (s, 3H), 0.88 (s, 3H).   
13C NMR (101 MHz, CDCl3) δ 166.1, 158.7, 148.9, 122.2, 81.1, 
80.3, 75.2, 74.2, 70.5, 61.1, 58.0, 57.8, 54.5, 51.8, 44.2, 40.2, 
38.5, 38.4, 34.9, 33.8, 31.8, 28.8, 26.4, 23.2, 22.2, 21.2, 20.7, 
20.3, 15.2, 13.8, 12.6. HRMS (ESI): Exact mass cald for 
C31H44NO6 [M+H]+, 526.3. Found 526.3. 
Analytical data for (E)-7: TLC Rf = 0.46 (50% 
EtOAc/pentanes, CAM stain). mp = 199−202 °C 
(decomposition). [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 = +36.7° (c = 0.15, CHCl3). IR (film) 𝜈𝜈� = 2938, 2361, 2341, 2115, 2048, 1985, 1705, 1458, 1425, 
1385, 1319, 1290, 1183, 1099, 1046, 1008, 895, 760, 732, 685, 
631   cm-1. 1H NMR (400 MHz, CDCl3) δ 4.71 – 4.59 (m, 2H), 
4.20 (dd, J = 13.3, 3.5 Hz, 1H), 3.29 (dd, J = 3.9, 2.2 Hz, 1H), 
3.18 (dd, J = 17.1, 6.1 Hz, 1H), 2.98 (d, J = 3.8 Hz, 1H), 2.86 
(d, J = 1.9 Hz, 1H), 2.56 – 2.32 (m, 5H), 2.16 – 1.99 (m, 4H), 
1.95 (s, 3H), 1.89 (s, 3H), 1.88 – 1.73 (m, 2H), 1.66 – 1.53 (m, 
2H), 1.49 (dd, J = 9.6, 9.6 Hz, 1H), 1.44 – 1.34 (m, 2H), 1.30 
(s, 3H), 1.27– 1.19 (m, 2H), 1.16 – 1.07 (m, 1H), 0.93 (s, 3H), 
0.89 (s, 3H).   13C NMR (101 MHz, CDCl3) δ 166.1, 158.4, 
148.9, 122.2, 81.1, 80.3, 75.2, 74.2, 70.4, 61.1, 57.9, 57.6, 54.5, 





21.2, 20.7, 20.6, 20.4, 14.9, 13.8, 12.6.   HRMS (ESI): Exact 
mass cald for C31H44NO6 [M+H]+, 526.3. Found 526.3.  





7-yl)-2,3-dimethylhepta-2,4-dienoate (8): To a solution of 
withanolide A (1, 30 mg, 0.063 mmol) dissolved in CH2Cl2 
(anhydrous, 7 mL, 0.009 M) in a round bottom flask with stir 
bar at room temperature was added nBu4NI (3 mg, 0.006 mmol, 
0.1 equiv.), a 50% NaOH solution (3.5 g in 7 mL H2O, 0.009 
M) and then the propargyl bromide (8 μL, 0.070 mmol, 1.1 
equiv.). The faint yellow reaction stirred for 3 days. Then, 
added 5 mL of sat. NH4Cl solution (aq.) and brought the mixture 
to pH of 7 with conc. HCl and 2M HCl. The aqueous layer was 
extracted with EtOAc (3×). The combined organic layers were 
washed with brine (1×), dried over MgSO4, filtered and 
concentrated in vacuo to afford a yellow oil. This was then 
purified by flash column chromatography with silica gel (×200) 
with 20, 30 and 40% EtOAc/pentanes as the eluent. Collected 
the unsaturated propargyl ester 9 (1.4 mg, 5% yield) as a yellow 
oil, propargyl ester 8 (10.6 mg, 33% yield) as a white solid, and 
starting material (8.4 mg, 28% mass recovery of 1).  
Analytical data for 8: TLC Rf = 0.44 (50% 
EtOAc/pentanes, CAM stain). mp = 156-158 °C. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 = –
6.5° (c = 0.265, CHCl3). IR (film) 𝜈𝜈� = 3730, 3592, 3485, 3271, 
2927, 2874, 2851, 2361, 2340, 2198, 2166, 1687, 1456, 1383, 
1291, 1262, 1215, 1105, 1033, 975, 906, 785, 630 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 7.01 (d, J = 15.9 Hz, 1H), 6.59 (ddd, 
J = 10.1, 5.1, 2.2 Hz, 1H), 6.01 (d, J = 15.8 Hz, 1H), 5.85 (dd, 
J = 10.2, 2.1 Hz, 1H), 4.77 (d, J = 2.5 Hz, 1H), 3.30 (dd, J = 
3.7, 2.0 Hz, 1H), 3.13 (d, J = 1.5 Hz, 1H), 3.03 (d, J = 3.9 Hz, 
1H), 2.76 – 2.64 (m, 2H), 2.56 – 2.47 (m, 1H), 2.48 (dd, J = 2.5, 
2.5 Hz, 1H), 2.12 – 2.02 (m, 2H), 1.99 (s, 3H), 1.98 – 1.93 (m, 
1H), 1.91 (d, J = 1.1 Hz, 3H), 1.88 – 1.60 (m, 4H), 1.48 – 1.41 
(m, 2H), 1.40 (s, 3H), 1.36 – 1.24 (m, 3H), 1.17 (s, 3H), 0.88 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 203.3, 168.7, 141.3, 141.1, 
139.7, 129.2, 125.8, 124.7, 78.1, 75.6, 74.9, 73.4, 59.7, 57.5, 
56.4, 52.0, 51.9, 51.2, 43.7, 40.4, 36.9, 35.7, 35.2, 28.9, 23.3, 
23.3, 21.8, 16.7, 16.1, 14.9, 14.2. HRMS (ESI): Exact mass 





dimethylhepta-2,4-dienoate (9): Analytical data for 9: TLC Rf 
= 0.83 (50% EtOAc/pentanes, CAM stain). [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐°𝑪𝑪 = –59.6° (c 
= 0.085, CHCl3). IR (film) 𝜈𝜈� = 3733, 3597, 3453, 3302, 2926, 
2871, 2480, 2361, 2334, 1711, 1662, 1625, 1567, 1454, 1380, 
1292, 1214, 1106, 1076, 973, 889, 767, 630 cm-1. 1H NMR (400 
MHz, CDCl3) δ 7.01 (d, J = 15.9 Hz, 1H), 6.93 (dd, J = 9.7, 6.0 
Hz, 1H), 6.42 (d, J = 5.9 Hz, 1H), 6.00 (d, J = 16.0 Hz, 1H), 
5.96 (dd, J = 9.7, 0.8 Hz, 1H), 4.77 (d, J = 2.5 Hz, 2H), 3.57 (d, 
J = 3.9 Hz, 1H), 3.31 (dd, J = 3.8, 1.4 Hz, 1H), 2.49 (dd, J = 
2.5, 2.5 Hz, 1H), 2.14 – 2.03 (m, 2H), 1.99 (s, 3H), 1.98 – 1.88 
(m, 1H), 1.91 (s, 3H), 1.89 – 1.82 (m, 1H), 1.77 – 1.65 (m, 2H), 
1.61 (dd, J = 11.0, 8.6 Hz, 1H), 1.54 – 1.47 (m, 1H), 1.45 – 1.40 
(m, 2H), 1.38 (s, 3H), 1.36 – 1.22 (m, 2H), 1.21 (s, 3H), 0.90 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 204.4, 168.7, 151.5, 141.3, 
141.0, 138.9, 127.1, 125.9, 124.7, 124.2, 78.1, 75.7, 75.0, 59.7, 
54.8, 52.4, 52.0, 51.8, 51.0, 43.5, 40.1, 37.4, 35.1, 28.9, 23.5, 
23.4, 21.3, 19.6, 16.7, 16.1, 14.0. HRMS (ESI): Exact mass 
cald for C31H38NaO5 [M+Na]+, 513.3. Found 513.3. 
4.5. Single crystal X-ray analyses of (Z)-7 and 8 
Selected crystallographic data of (Z)-7 are summarized as 
follows: molecular formula C31H43NO6, Mw 525.69, 
wavelength Cu Kα, (λ = 1.54178 Å), Monoclinic, P21, a: 
6.3281(3) Å, b: 7.4242(4) Å, c: 28.7295(12) Å, α 90°, β 
95.892(3)°, γ 90°, V = 1342.61 Å3, Dcacld = 1.300 mg/m-3, F(000 
) = 568, µ = 0.717 mm-1, T = 123 K.  
Selected crystallographic data of 8 are summarized as 
follows: molecular formula C31H40O6, Mw 508.65, wavelength 
Cu Kα, (λ = 1.54178 Å), Orthorhombic, P212121, a: 6.2944(3) 
Å, b: 11.7168(5) Å, c: 35.5369(17) Å, α 90°, β 90°, γ 90°, V = 
2620.9(2) Å3, Dcacld = 1.289 mg/m-3, F(000 ) = 1096, µ = 0.708 
mm-1, T = 123 K. 
Data collection was performed by Dr. Markus Neuburger 
(University of Basel) on a Bruker Kappa APEX diffractometer. 
by placing the crystal in the cold stream (123K) of Oxford 
Cryosystems open-flow nitrogen cryostat with nominal stability 
of 0.1K.97 The absorption process applied to the intensities was 
SADABS.98 Integration of the frames and data reduction was 
carried out using APEX2.99 The structures were solved by direct 
methods using Superflip.100 All non-hydrogen atoms were 
refined anisotropically by full-matrix least-squares on F using 
CRYSTALS,101 and computing molecular graphics were done 
using CAMERON.102 The data can be obtained free of charge 
from The Cambridge Crystallographic Data Centre via www. 
ccdc.cam.ac.uk/data_request/cif.  
4.6. Affinity-based protein profiling tests 
Human cells A549 were grown in DMEM medium (Sigma 
Life Sciences) with 2 mM glutamine (PAA) and 10 % fetal 
bovine serum (Sigma Life Sciences) for analytical (6 well) and 
for preparative (TC dish 150 standard) studies, respectively. For 
SILAC studies, SILAC medium (Gibco, Life Technologies) 
with 2 mM glutamine (PAA), 10% dialysed fetal bovine serum 
(Sigma Life Sciences) and isotope labelled amino acids (K0, 
K4, K6, R0, R8, R10; euriso-top) were used. The cells were 
grown to 70-80 % confluence. Cells were incubated for 1 h with 
varying concentrations of probe (stock solution in DMSO, 0.1% 
end concentration of DMSO) in a cell incubator at 37 °C. 
Subsequently, the cells were scraped off and pelletized for 3 
min at 600 g. The pellets were washed with PBS once and then 
resuspended in lysis buffer (1% (v/v) NP40 and 1% (w/v) 
sodium deoxycholate) and incubated at 0 °C for 15 min. 
Membrane and cytosol were separated by centrifugation (20 
min, 4 °C, 21·103 xG). The membrane fraction was washed 
once with PBS (1 × 10 sec, 10% maximum intensity) and 






4.7. VirtualToxLab studies 
Version 5.8 of VirtualToxLab was used for the data 
presented in this paper. The simulations are conducted at the 
atomic level and explicitly allow for a mechanistic 
interpretation of the results. The underlying protocol is 
independent from any training data and makes the approach 
universal with respect to the applicability domain. Overall, a 
toxic potential of a compound is derived from the binding 
affinities (computed by means of 4D Boltzmann scoring of all 
binding modes identified through automated, flexible docking 
to the 3D structure of the target protein) towards a series of 16 
proteins known to trigger adverse effects and weighted using 
the standard deviations of the individual predictions. The 
individual target proteins screened include: Androgen receptor 
(AR), Aryl hydrocarbon receptor (AhR), Cytochrome P450 
1A2 (CYP1A2), Cytochrome P450 2C9 (CYP2C9), 
Cytochrome P450 2D6 (CYP2D6), Cytochrome P450 3A4 
(CYP3A4), Estrogen receptor α (ERα), Estrogen receptor β 
(ERβ), Glucocorticoid receptor (GR), hERG, Liver X receptor 
(LXR), Mineralocorticoid receptor (MR), Peroxisome 
Proliferator-Activated receptor γ (PPARγ), Progesterone 
receptor (PR), Thyroid receptor α (TRα), Thyroid receptor β 
(TRβ). Except for AhR and hERG (for which homology models 
are employed), all simulations are based on high-resolution 
crystal structures from the PDB. 
4.8. Neurite outgrowth GR competition assay 
Human neuroblastoma SH-SY5Y cells (ATCC-CRL-
2266) were grown in DMEM/F-12 media (Dulbecco’s 
Modified Eagle Medium F12 Nutrient Mixture HAM, with high 
glucose and phenol red, without glutamine and HEPES; GIBCO 
Life Technologies 21331-020) supplemented with 10% fetal 
bovine serum (FBS South American CE, 10270106 Gibco Life 
Technologies) and 1% Penicillin-Streptomycin (10,000 U/mL, 
Life Technologies 15140-122) in canted neck culture flasks 
with vented cap (75 cm2, Falcon 353136). Cells were passaged 
at least three times before use in experiments; for this, 0.25% 
Trypsin-EDTA solution (Sigma-Aldrich T3924) and 
Dulbecco’s phosphate-buffered saline (DPBS, 1X, without 
Ca/Mg, pH 7.2, Sigma-Aldrich D8537) were used. 
All experiments were performed under strictly sterile 
conditions. The cells were plated at an optimal concentration of 
5 × 105 cells/mL onto Collagen I, coated 24-well plates (Gibco 
Life Technologies A11428-02) in the presence of the 
corresponding compounds (1 µM concentration, 0.1% DMSO) 
to a total well volume of 1 mL, at 37 °C in a humidified 
atmosphere (5% CO2 content). For the control experiments, 
cells were treated with DMSO vehicle (0.1%) as the negative or 
all-trans Retinoic acid (ATRA, Aldrich R2625) as a positive 
control. The glucocorticoid receptor (GR) control compounds 
used were dexamethasone (Dex, Sigma-Aldrich D4902) and 
mifepristone (Mife, RU-486, Sigma-Aldrich M8046). 
After a 6-day incubation, the media (1 mL total volume) 
was aspirated from each of the 24-well plates and washed with 
PBS (DPBS). The PBS was removed by aspiration, and the cells 
were fixed with neutral buffered formaldehyde 4% solution 
(10% formalin, Sigma-Aldrich HT5012; 500 µL) dropped 
slowly down the side of the well. The plates were incubated at 
room temperature for 1–2.5 hours and then washed with PBS (1 
× 500 µL). The plates were then stained with a thin-layer of 
Giemsa stain (modified solution, Sigma-Aldrich GS500, 100 
µL; previously filtered through a VWR 0.2 µm PES sterile 
syringe filter and diluted with MeOH) to visualize the cell 
bodies. After 2 minutes, the stain was diluted with PBS (500 
µL) and, after gentle swirling for 2 minutes, the solution was 
removed by aspiration. The plates were then washed with PBS 
(1 × 500 µL) and imaged under PBS by phase contrast 
microscope (160× magnification, Leica DMI 4000B, 
Germany). When it was necessary, the PBS was aspirated off 
an additional time and replaced with a fresh layer. 
All assays were performed in triplicate, with 6−11 images 
randomly taken between the three wells, and at least 350 cells 
counted per treatment per plate (three wells/plate per treatment). 
Those cells having at least one neurite with a length of more 
than 50 µm were counted as differentiated (positive). The ratio 
of neurite positive cells to total cells was evaluated with cell 
counting tool in ImageJ, and error is represented by the standard 
error of the mean (SEM). Large cell aggregates were not 
counted. Plots were drawn using Microsoft Excel. The 
significance of the results was examined by ANOVA and post 
hoc tests (Dunnett’s Method and Tukey Kramer Method) using 
Excel. All treatments were significantly different than the 
DMSO control. 
4.9. GR lysate binding bioassay 
Recombinant human glucocorticoid receptor α (GR) 
Baculovirus stock was produced using Bac-to-Bac expression 
system (Invitrogen). For lysate preparation cells were collected 
in ice-cold PBS and centrifuged at 3000 g, 4 °C, 10 min, 
resuspended in binding buffer (pH 7.4, 50 mM HEPES, 10 mM 
EDTA, 50 mM sodium tungstate, 50% glycerol) and 
homogenized using a glass puller with 50 strokes. The lysate 
was centrifuged (16,000 g, 10 min, 4 °C) and supernatants 
stored at −80 °C.  
Recombinant human GR lysate was incubated in the 
presence of 10 nM [1,2,4,6,7-3H]-Dexamethasone (American 
Radiolabeled Chemicals, St. Louis, MO) and unlabeled 
competitor (either 10 µM Dex or 10 µM respectively 1 µM 
Withanolide A) for 4 h at 16 °C. Free concentration of ligand 
was separated by adding 5% dextran coated charcoal in binding 
buffer and incubation on ice for 10 min following centrifugation 
at 3200 g, 4 °C for 10 min. The GR bound fraction of 
radioligand in supernatants was measured by scintillation 
counting. 
4.10. GR and MR transactivation bioassay 
HEK-293 cells were seeded in poly-L-lysine-coated 24 
well plates. Each well contained 80’000 cells cultivated in 500 
μL DMEM supplemented with 10% FBS. After 24 h, cells were 
transfected with 281 ng of TAT3 TATA Luc control plasmid, 
and 188 ng of plasmid for human GR-α or MR expression using 
FuGENE (Promega). 24 hours later, cells were washed twice 
with steroid-free medium, followed by incubation for another 





MR, 100 nM cortisol for GR), receptor antagonist (1 µM 
spironolactone for MR and 1 µM Mife for GR) or 1 µM of 
Withanolide A. Cells were lysed in 60 µL of tropix lysis 
solution (Applied Biosystems, Foster City, CA) supplemented 
with 0.5 µM dithiothreitol.  
Luciferase activity was determined in 20 μl lysate adding 
100 μl of D-luciferin-firefly substrate solution at a final 
concentration of 0.47 mM D-luciferin, 53 mM ATP, 0.27 mM 
coenzyme A, 0.13 mM EDTA, 33.3 mM dithiothreitol, 20 mM 
tricine, pH 7.8, and 8 mM MgSO4. Samples were measured 
using a SpectraMax-L luminometer (Molecular Devices, 
Devon, UK). Luciferase activities were used to calculate fold 
activation compared with vehicle control (0.05% DMSO). 
4.11. GR docking studies 
Docking was performed using the GOLD 5.2 software 
(Chambridge Crystallographic Data Centre, Cambridge, UK). 
This program applies a genetic algorithm for the identification 
of accurate docking poses for small molecules into the binding 
pocket of a protein. The crystal structure of GR with the PDB 
entry 1M2Z was chosen because the initial screenings with the 
VirtualToxLab were based on this structure. First, the co-
crystallized ligand Dexamethasone was docked to investigate 
whether GOLD could restore the original binding orientation 
and therefore validate the docking settings. The binding site was 
centered on the carbonyl-oxygen of Asn564 (x 27.23; y 3.52; z 
13.23) surrounded by a 9 Å sphere. GoldScore was selected as 
scoring function. Interactions found for the docking solutions 
between the ligands and the GR binding pocket were evaluated 
using LigandScout 3.12. This program automatically analyzes 
the observed interaction pattern between the docked ligand and 
the protein, based on the chemical functionalities, the geometric 
distances and the angles between neighboring structures.102 
Appendix A. Supplementary Data 
Supplementary data can be found online at 
http://doi.org/xxx/j.bmc.xxx. The probe synthesis, NMR 
spectra, characterization, target profiling, VirtualToxLab and 
docking studies, and all bioassays are described in this article. 
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